IAPT Rec'd PCT/PTO 04 APR 2006

Form PTO (REV 5-93)			attorney's docket number PU60525						
	RANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/574676						
	ATIONAL APPLICATION NO. JS04/032824	INTERNATIONAL FILING DATE 6 October 2004	PRIORITY DATE CLAIMED 6 October 2003						
TITLE O Prepa	FINVENTION tration of 1,6 Disub	estituted Azabenzimidazol	les as Kinase Inhibitors						
Denni	ANT(S) FOR DO/EO/US S LEE; Robert A. STAV Andrew Q. VIET	/ENGER;Krista B. GOODMA	AN;Mark A. HILFIKER;Haifeng						
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
2. [] 3. [x]	This is a <b>SECOND</b> or <b>SUB</b> This express request to begin	in national examination procedures (expiration of the applicable time lin	ncerning a filing under 35 U.S.C. 371. (35 U.S.C. 371(f)) at any time rather than						
5. [x]	<ul><li>a. [] is transmitted herew</li><li>b. [] has been transmitted</li></ul>	Application as filed (35 U.S.C. 371) with (required only if not transmitted by the International Bureau. The application was filed in the United							
6. []	A translation of the Internat	ional Application into English (35 U	J.S.C. 371(c)(2)).						
7. [x] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))  a. [] are transmitted herewith (required only if not transmitted by the International Bureau).  b. [] have been transmitted by the International Bureau.  c. [] have not been made; however, the time limit for making such amendments has NOT expired.  d. [x] have not been made and will not be made.									
9. [x]	An oath or declaration of th a. [x] was submitted as p A translation of the annexes	nents to the claims under PCT Article inventor(s) (35 U.S.C. 371(c)(4)). Part of the international application us to the International Preliminary Example 2.							
;; T4	U.S.C. 371(c)(5)).	and a second second second second							
11. [x]	<ul> <li>[x] An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.</li> <li>[An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</li> </ul>								
14. []		dment.  Preliminary Amendment for US  ENT preliminary amendment.	originating cases only)						
17. [x] 18. [x]	Power of attorney. An Abstract on a separate s Copy of Form PCT/ISA/210 Other items or information.								
12. []	Once items of information.								

## IAP20 RES'S FOURTO O 4 APR 2005.

US APPLICATION	APPLICATION NO. (if known see 37 CFR 1.50) INTERNATIONAL APPLICATION NO. PCT/US04/032824		ATTORNEYS DOCKET NO. PU60525		
20. [X] The following fees are submitted:				CALCULATION	PTO USE ONLY
	National Fee (37 C.F.				
■ Basic	Filing Fee	\$300.00			
Exami	nation Fee				
	nal Preliminary Examination				
	visions of PCTArtlice33(1)	\$200.00			
	uations				
: 🗷 Search					
	37 CFR 1.445(a)(2) has be	\$100.00	440000		
	Search Report prepared a	\$100.00			
	uations				
	T	\$600.00	<del></del>		
Surcharge of \$13	30.00 for furnishing the	oath or declaration la	ater than 20 30	\$0.00	
	earliest claimed priority			40,00	
Claims	Number Filed	Number Extra	Rate		
Total claims	7 - 20 =	0	0 x \$50.00	\$0.00	
Independent claims	- 3 =	0	0 x \$200.00	\$0.00	
Multiple depende	ent claims (if applicable	\$0.00			
-		\$600.00			
	pplication size fee-for e sheets. The fee is \$250		eets (including drawings) nal 50 sheets or fraction	\$0.00	
		\$600.00			
	f \$130.00 for furnishing				
	ths from the earliest cla		77 CFR 1.492(f)) + FAL NATIONAL FEE =		
		\$600.00			
				Amount to be	\$
				Amount to be refunded charged	\$

- Please charge my Deposit Account No. <u>19-2570</u> in the amount of <u>\$600.00</u> to cover the above fees.
  - The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570.
- d. General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:** 

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-7481

Facsimile (610) 270-5090

SIGNATURE

Reid S. Willis

NAME

39,429

REGISTRATION NO.

# 10/574676

### IAP20 Rec'd POTAPTO 04 APR 2006

PATENT

ATTORNEY'S DOCKET NUMBER PU60525

## TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US04/032824 6 October 2004 6 October 2003

TITLE OF INVENTION

Preparation of 1,6 Disubstituted Azabenzimidazoles as Kinase Inhibitors

APPLICANT(S) FOR DO/US

Dennis LEE; Robert A. STAVENGER; Krista B. GOODMAN; Mark A. HILFIKER; Haifeng CUI; Andrew Q. VIET

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

1

4

\_Alexandria, VA 22313-1450 ATTENTION: DO/US

#### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date <u>April 4, 2006</u> in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EV687882930US</u> addressed to the:

OMANOWSKI ....

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)

20462

CUSTOMER NUMBER